Re: Notes and comments on Efficacy, Safety, and Comparison of Sonic Hedgehog Inhibitors in Basal Cell Carcinomas: A Systematic Review and Meta-Analysis

Author(s):  
Philippe Lefrançois ◽  
Pingxing Xie ◽  
Khue H. Nguyen
2019 ◽  
Vol 31 (6) ◽  
pp. 597-601
Author(s):  
Kevin Phan ◽  
Lawrence J. Oh ◽  
Sourabh Goyal ◽  
Tim Rutherford ◽  
Anousha Yazdabadi

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Paul J. Wirth ◽  
Ryan Hobbs ◽  
Elizabeth Billingsley ◽  
Allison T. Vidimos ◽  
Charlene Lam

2021 ◽  
Vol 4 (7) ◽  
pp. e202000651
Author(s):  
Ivan V Litvinov ◽  
Pingxing Xie ◽  
Scott Gunn ◽  
Denis Sasseville ◽  
Philippe Lefrançois

Basal cell carcinoma (BCC) is the most common skin cancer and human malignancy. Although most BCCs are easily managed, some are aggressive locally, require Mohs micrographic surgery, or can even metastasize. In the latter, resistance to Sonic Hedgehog inhibitors may occur. Despite their frequent occurrence in clinical practice, their transcriptional landscape remains poorly understood. By analyzing BCC RNA sequencing data according to clinically important features (all BCCs versus normal skin, high-risk versus low-risk BCCs based solely on histopathological subtypes with aggressive features, advanced versus non-advanced BCCs, and vismodegib-resistant versus vismodegib-sensitive tumors), we have identified novel differentially regulated genes and new targetable pathways implicated in BCC tumorigenesis. Pathways as diverse as IL-17, TLR, Akt/PI3K, cadherins, integrins, PDGF, and Wnt/β-catenin are promising therapeutic avenues for local and systemic agents in managing this common malignancy, including through drug re-purposing of existing medications. We experimentally validated several of these targets as biomarkers in our patient-derived cohort of primary BCC tumors.


2020 ◽  
Vol 33 (6) ◽  
Author(s):  
George Mpourazanis ◽  
Pantelis Mpourazanis ◽  
Georgios Stogiannidis ◽  
Georgios Ntritsos

Sign in / Sign up

Export Citation Format

Share Document